

APB084Hu02 100μg

Active Galanin (GAL)

Organism Species: Homo sapiens (Human)

Instruction manual

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

[PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Ala20~Ser123 Tags: N-terminal His-tag

Purity: >90%

Endotoxin Level: <1.0EU per 1µg (determined by the LAL method).

Buffer Formulation: PBS, pH7.4, containing 0.01% Sarcosyl, 5%Trehalose.

Original Concentration: 200µg/mL

Applications: Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.8

Predicted Molecular Mass: 15.2kDa

Accurate Molecular Mass: 17kDa as determined by SDS-PAGE reducing conditions.

[<u>USAGE</u>]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.



Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

ASAGLWSPAKEKRGWTLNSAGYLLGPHAVGNHRSFSDKNGLTSKRELRPEDD MKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGALDRLLDLPAAASSEDIERS

[ACTIVITY]

Galanin (GAL) is a neuropeptide widely distributed in the central and peripheral nervous systems. It consists of 29 or 30 amino acids and is involved in various physiological processes like regulating appetite, pain sensation, memory, and endocrine function.Besides,Galanin Like Peptide (GALP) has been identified as an interactor of GAL, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human GAL and recombinant rat GALP. Briefly, biotin-linked GAL were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 μ I were then transferred to GALP-coated microtiter wells and incubated for 1h at 37 $^{\circ}\!\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!^{\circ}\!\!\!$. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 $^{\circ}\!\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!\!^{\circ}\!\!\!^{\circ}\!\!\!\!^{\circ}$




Figure 1. The binding activity of recombinant human GAL and recombinant rat GALP

[IDENTIFICATION]




Figure 2. Gene Sequencing (extract)

Cloud-Clone Corp.




Figure 3. SDS-PAGE

Sample: Active recombinant GAL, Human

[IMPORTANT NOTE]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.